Anthropic has acquired Mithril Medicine, a biotechnology company using artificial intelligence (AI) to develop experimental treatments for rare muscular dystrophy conditions. Completed in July, Anthropic’s Acquisition of Mithril Medicine marks Anthropic’s move into internal drug development using its Claude AI system.
Founded by Cody Tranbarger, Mithril Medicine used Claude to coordinate research across 11 external laboratories, taking a potential muscular dystrophy treatment. Anthropic plans to continue the research, with the first candidate potentially entering human clinical trials as early as late 2028.
Why Did Anthropic Acquire Startup Mithril Medicine?
Mithril Medicine had one full-time employee, Tranbarger, who worked with scientific consultants and external laboratories to manage its research programs. Claude supported tasks such as organizing contracts, coordinating experiments, managing logistics, and analyzing research information.
Anthropic described the approach as “Pipeline-in-a-Person,” a model that uses AI to help a small team coordinate multiple stages of drug development.
Anthropic’s acquisition of Mithril Medicine also gives the company a direct responsibility for research into two rare muscle disorders: LAMA2-related congenital muscular dystrophy and alpha-dystroglycanopathy. Tranbarger has joined Anthropic to continue the existing programs and plans to launch additional research projects.
How Will Claude and Mithril Support Muscular Dystrophy Research?
Mithril Medicine’s first reported results focus on LAMA2-related congenital muscular dystrophy, a genetic condition in which changes in the LAMA2 gene weaken the connections between muscle fibers and surrounding tissue.
The research uses bispecific antibodies, engineered proteins designed to bind two different targets. In this case, the antibodies aim to help restore connections that support muscle function.
According to Anthropic’s preliminary research report, one antibody format produced encouraging results in mice:
- Seven treated mice showed approximately twice the grip strength and peak triceps force of four control mice.
- Researchers reported reaching an early proof of principle in less than 18 months.
- The technical report remains awaiting peer review.
However, the findings from muscular dystrophy treatment research require careful interpretation. Researchers did not randomly assign the animals to treatment groups, and they tested the groups at different times. These differences make it difficult to attribute the observed improvements solely to the treatment. The report calls for further testing under concurrent, blinded conditions.
Anthropic’s research results therefore are an early milestone, not proof that the treatment will work in humans.
When Could Mithril Medicine Treatments Enter Human Trials?
Anthropic has outlined the following development targets for its experimental Muscular Dystrophy treatments:
- 2027: Mithril aims to select formal drug candidates.
- Late 2028: The LAMA2-related muscular dystrophy program could enter human clinical trials at the earliest.
- 2029: The alpha-dystroglycanopathy program targets potential entry into clinical trials.
These dates depend on successful further development and are not confirmed dates to start human trials. Researchers must establish sufficient evidence to support clinical testing before evaluating the treatments in people.
How Does Anthropic AI Expand Across Healthcare?
Anthropic’s acquisition of Mithril Medicine forms part of Anthropic’s broader strategy to apply AI throughout drug development, from early scientific research to manufacturing documentation and clinical trial planning.
In its recent update, Anthropic described collaborations with six organizations, which include BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group.
Anthropic reported several early results from these partnerships. For example, Claude generated approximately 35,000 antibody designs in about a month for food-allergy research with Divergence Labs. Separately, Enveda reported that a Claude-powered workflow reduced review time for manufacturing records by 89% in a specific evaluation.
Anthropic is also making research tools available through Claude Science, its AI workbench for researchers, alongside initiatives intended to support life sciences research.
What Are The Challenges Ahead for AI-Powered Drug Discovery?
Despite the reported progress, Mithril’s experimental treatments remain in the preclinical stage, meaning researchers have not yet established their safety or effectiveness in humans.
AI can help organize complex research, but its outputs can contain errors. Anthropic’s research report describes mistakes in laboratory instructions and data reviews, highlighting the continuing need for expert oversight and independent validation.
Anthropic’s acquisition of Mithril Medicine allows the company to test whether Claude-assisted research can accelerate rare disease drug development. Its long-term impact will depend on reproducible scientific results, successful clinical testing, and evidence that the treatments benefit patients.
